Large Intestine Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LRG016 MIFTS: 42	Large Intestine Adenocarcinoma Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases
Genes Tissues Related diseases Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Large Intestine Adenocarcinoma

MalaCards integrated aliases for Large Intestine Adenocarcinoma:

Name: Large Intestine Adenocarcinoma ¹² ¹⁵

Adenocarcinoma of Large Intestine ⁷⁴

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Gastrointestinal diseases Endocrine diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0050913

UMLS ⁷⁴ C1319315

Sources

Summaries for Large Intestine Adenocarcinoma

Disease Ontology : ¹² A large intestine cancer that has material basis in epithelial cells of glandular origin.

MalaCards based summary : Large Intestine Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to rare adenocarcinoma of the breast and malignant spiradenoma. An important gene associated with Large Intestine Adenocarcinoma is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Iron and Hematinics have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and lung, and related phenotypes are behavior/neurological and cardiovascular system

Sources

Related Diseases for Large Intestine Adenocarcinoma

Diseases in the Large Intestine Adenocarcinoma family:

Small Intestine Adenocarcinoma

Diseases related to Large Intestine Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)

#	Related Disease	Score	Top Affiliating Genes
1	rare adenocarcinoma of the breast	10.2	PIK3CA TP53
2	malignant spiradenoma	10.2	PIK3CA TP53
3	female reproductive endometrioid cancer	10.2	CTNNB1 TP53
4	anal squamous cell carcinoma	10.2	PIK3CA TP53
5	ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3	10.2	PIK3CA TP53
6	esophageal basaloid squamous cell carcinoma	10.1	CTNNB1 TP53
7	embryonal sarcoma	10.1	CTNNB1 TP53
8	tongue disease	10.1	CTNNB1 TP53
9	acinar cell carcinoma	10.1	CTNNB1 TP53
10	prostate transitional cell carcinoma	10.1	CTNNB1 PIK3CA
11	gastrointestinal system benign neoplasm	10.1	CTNNB1 TP53
12	intestinal benign neoplasm	10.1	CTNNB1 TP53
13	skin squamous cell carcinoma	10.1	PIK3CA TP53
14	hemimegalencephaly	10.1	CTNNB1 PIK3CA
15	penile cancer	10.1	PIK3CA TP53
16	gastric papillary adenocarcinoma	10.1	ERBB2 TP53
17	papillary adenocarcinoma	10.1	ERBB2 TP53
18	infratentorial cancer	10.1	CTNNB1 TP53
19	ovarian clear cell carcinoma	10.1	PIK3CA TP53
20	pleomorphic adenoma	10.1	ERBB2 TP53
21	pleomorphic adenoma carcinoma	10.1	ERBB2 TP53
22	non-proliferative fibrocystic change of the breast	10.1	ERBB2 TP53
23	nasopharyngeal disease	10.1	CTNNB1 TP53
24	atypical teratoid rhabdoid tumor	10.1	CTNNB1 TP53
25	glioma susceptibility 1	10.1	ERBB2 TP53
26	brain stem glioma	10.1	PIK3CA TP53
27	microglandular adenosis	10.1	ERBB2 TP53
28	esophagus adenocarcinoma	10.1	ERBB2 TP53
29	breast benign neoplasm	10.1	ERBB2 TP53
30	thoracic benign neoplasm	10.1	ERBB2 TP53
31	pharynx cancer	10.1	CTNNB1 TP53
32	mixed cell type cancer	10.1	ERBB2 TP53
33	cervix disease	10.1	CTNNB1 TP53
34	epstein-barr virus-associated gastric carcinoma	10.1	CTNNB1 PIK3CA
35	granulosa cell tumor of the ovary	10.1	ERBB2 TP53
36	hidradenocarcinoma	10.1	ERBB2 TP53
37	adenosquamous carcinoma	10.1	PIK3CA TP53
38	primary peritoneal carcinoma	10.1	ERBB2 TP53
39	tonsil cancer	10.1	ERBB2 TP53
40	pre-malignant neoplasm	10.1	ERBB2 TP53
41	fallopian tube carcinoma	10.1	ERBB2 TP53
42	cervical squamous cell carcinoma	10.1	CTNNB1 TP53
43	barrett's adenocarcinoma	10.1	ERBB2 TP53
44	peutz-jeghers syndrome	10.1	CTNNB1 TP53
45	lobular neoplasia	10.1	CTNNB1 ERBB2
46	acneiform dermatitis	10.1	ERBB2 PIK3CA
47	colorectal adenoma	10.1	CTNNB1 TP53
48	in situ carcinoma	10.1	ERBB2 TP53
49	cell type benign neoplasm	10.0	CTNNB1 TP53
50	breast carcinoma in situ	10.0	ERBB2 TP53

Graphical network of the top 20 diseases related to Large Intestine Adenocarcinoma:

Sources

Symptoms & Phenotypes for Large Intestine Adenocarcinoma

MGI Mouse Phenotypes related to Large Intestine Adenocarcinoma:

⁴⁷ (show all 15)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	9.95	CREBBP CTNNB1 ERBB2 PIK3CA TP53
2	cardiovascular system	MP:0005385	9.93	CREBBP CTNNB1 ERBB2 PIK3CA TP53
3	cellular	MP:0005384	9.92	CREBBP CTNNB1 ERBB2 PIK3CA TP53
4	embryo	MP:0005380	9.88	CREBBP CTNNB1 ERBB2 PIK3CA TP53
5	endocrine/exocrine gland	MP:0005379	9.85	CREBBP CTNNB1 ERBB2 PIK3CA TP53
6	growth/size/body region	MP:0005378	9.83	CREBBP CTNNB1 ERBB2 PIK3CA TP53
7	craniofacial	MP:0005382	9.81	CREBBP CTNNB1 ERBB2 TP53
8	digestive/alimentary	MP:0005381	9.8	CREBBP CTNNB1 ERBB2 TP53
9	integument	MP:0010771	9.8	CREBBP CTNNB1 ERBB2 PIK3CA TP53
10	muscle	MP:0005369	9.72	CREBBP CTNNB1 ERBB2 PIK3CA TP53
11	limbs/digits/tail	MP:0005371	9.67	CREBBP CTNNB1 ERBB2 TP53
12	neoplasm	MP:0002006	9.65	CREBBP CTNNB1 ERBB2 PIK3CA TP53
13	nervous system	MP:0003631	9.55	CREBBP CTNNB1 ERBB2 PIK3CA TP53
14	respiratory system	MP:0005388	9.26	CREBBP CTNNB1 ERBB2 TP53
15	skeleton	MP:0005390	9.02	CREBBP CTNNB1 ERBB2 PIK3CA TP53

Sources

Drugs & Therapeutics for Large Intestine Adenocarcinoma

Drugs for Large Intestine Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Iron

Approved, Experimental

Phase 4

7439-89-6, 15438-31-0

23925 27284

Hematinics

Phase 4,Phase 3,Phase 2,Phase 1

Hepcidins

Phase 4

Ferric Compounds

Phase 4

Iron Supplement

Phase 4

Bevacizumab

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

216974-75-3

Capecitabine

Approved, Investigational

Phase 3,Phase 2,Phase 1

154361-50-9

60953

Oxaliplatin

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

61825-94-3

6857599 5310940 9887054 43805

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

51-21-8

3385

Levoleucovorin

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

68538-85-2

leucovorin

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

58-05-9

6006 143

Irinotecan

Approved, Investigational

Phase 2, Phase 3,Phase 1

100286-90-6, 97682-44-5

60838

Atezolizumab

Approved, Investigational

Phase 3,Phase 2,Phase 1

1380723-44-3

Nicotine

Approved

Phase 3

54-11-5

942 89594

Panitumumab

Approved, Investigational

Phase 3,Phase 2

339177-26-3

50070211

Calcium

Approved, Nutraceutical

Phase 3,Phase 2

7440-70-2

271

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2,Phase 1

59-30-3

6037

Glutamic Acid

Approved, Nutraceutical

Phase 3

56-86-0

33032

Angiogenesis Modulating Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Angiogenesis Inhibitors

Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites

Phase 3,Phase 2,Phase 1,Not Applicable

Antineoplastic Agents, Immunological

Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1,Not Applicable

Immunologic Factors

Phase 3,Phase 2,Phase 1,Not Applicable

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antidotes

Phase 3,Phase 2,Phase 1

Protective Agents

Phase 3,Phase 2,Phase 1

Calcium, Dietary

Phase 3,Phase 2

Topoisomerase Inhibitors

Phase 2, Phase 3,Phase 1

topoisomerase I inhibitors

Phase 2, Phase 3,Phase 1

s 1 (combination)

Phase 3

Antibodies

Phase 3,Phase 1,Phase 2

Antibodies, Monoclonal

Phase 3,Phase 1,Phase 2

Immunoglobulins

Phase 3,Phase 1,Phase 2

Liver Extracts

Phase 3,Phase 2,Phase 1,Not Applicable

Pharmaceutical Solutions

Phase 3,Phase 2

Vitamins

Phase 3,Phase 2,Phase 1

Immunoglobulin G

Phase 3,Phase 2

Trace Elements

Phase 3,Phase 2,Phase 1

Hormones

Phase 3,Phase 2,Phase 1

Nutrients

Phase 3,Phase 2,Phase 1

Vitamin B Complex

Phase 3,Phase 2,Phase 1

Bone Density Conservation Agents

Phase 3,Phase 2

Mitogens

Phase 3,Phase 2,Phase 1

Micronutrients

Phase 3,Phase 2,Phase 1

Folate

Phase 3,Phase 2,Phase 1

Endothelial Growth Factors

Phase 3,Phase 2

Vitamin B9

Phase 3,Phase 2,Phase 1

Formyltetrahydrofolates

Phase 3

Tetrahydrofolates

Phase 3

Interventional clinical trials:

(show top 50) (show all 136)

#	Name	Status	NCT ID	Phase	Drugs
1	Intravenous Iron: Measuring Response in Anemic Surgical Patients	Completed	NCT02057471	Phase 4	Intravenous ferric carboxymaltose
2	IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia	Completed	NCT01701310	Phase 4	Ferric carboxymaltose;Ferrous Sulphate
3	Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma	Not yet recruiting	NCT03708536	Phase 3	S-1;Bevacizumab;Capecitabine
4	A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)	Completed	NCT02788279	Phase 3	Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
5	Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）	Active, not recruiting	NCT02390947	Phase 3	Famitinib;Placebo
6	Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases	Completed	NCT00265356	Phase 3
7	TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases)	Not yet recruiting	NCT03783559	Phase 3	TACE;chemotherapy±target therapy
8	Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM	Recruiting	NCT03125161	Phase 3	HAI;chemotherapy ± target therapy
9	A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer	Completed	NCT00623805	Phase 3	Bevacizumab;Capecitabine;Oxaliplatin
10	Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer	Recruiting	NCT02997228	Phase 3	Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin
11	5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab	Recruiting	NCT03300609	Phase 3	Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
12	Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases	Recruiting	NCT02758951	Phase 2, Phase 3
13	Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma	Unknown status	NCT01552967	Phase 2	Capecitabine
14	Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.	Unknown status	NCT01067053	Phase 2	bevacizumab, capecitabine, oxaliplatin
15	Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma	Unknown status	NCT00075556	Phase 2	capecitabine
16	Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)	Unknown status	NCT01929616	Phase 2	regorafenib
17	Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer	Unknown status	NCT00544011	Phase 2	capecitabine;fluorouracil;irinotecan hydrochloride
18	Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer	Unknown status	NCT00104689	Phase 2	capecitabine;oxaliplatin
19	Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer	Unknown status	NCT00027833	Phase 2	FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
20	Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal ADenocarcinoma	Recruiting	NCT01844076	Phase 1, Phase 2	Phase I (Quinacrine);Capecitabine
21	Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma	Completed	NCT00034190	Phase 2	S-8184 Paclitaxel Injectable Emulsion
22	Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma	Active, not recruiting	NCT01639131	Phase 2	Gemcitabine;Docetaxel;Filgrastim or Pegfilgrastim
23	Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .	Completed	NCT02788006	Phase 2	Regorafenib 160 mg
24	Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma	Active, not recruiting	NCT02023333	Phase 2	Regorafenib
25	Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)	Completed	NCT01900717	Phase 2	LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
26	Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma	Completed	NCT00168155	Phase 2	perioperative chemotherapy
27	Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma	Recruiting	NCT03559543	Phase 2
28	Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma	Terminated	NCT00102024	Phase 1, Phase 2	Unconjugated IDEC-159;111In-IDEC-159;90Y-IDEC-159
29	Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.	Completed	NCT02181465	Phase 2
30	Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies	Active, not recruiting	NCT02870920	Phase 2	Tremelimumab;Durvalumab
31	Chemotherapy and/or Metastasectomy in Treating Participants With Metastatic Colorectal Adenocarcinoma With Lung Metastases	Recruiting	NCT03599752	Phase 2	Chemotherapy
32	FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation	Recruiting	NCT03584711	Phase 2
33	Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma	Completed	NCT00574171	Phase 2	lapatinib;Capecitabine
34	A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver	Terminated	NCT01098422	Phase 2
35	Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma	Completed	NCT01479465	Phase 2	Simtuzumab;FOLFIRI;Placebo to match simtuzumab
36	Safety and Feasibility of Electrochemotherapy in Unresectable Colorectal Adenocarninoma Liver Metastases	Terminated	NCT02709811	Phase 1, Phase 2	Electrochemotherapy
37	Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases	Recruiting	NCT02185443	Phase 2
38	DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma	Completed	NCT00080834	Phase 2	DJ-927
39	Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy	Completed	NCT00419159	Phase 2	Everolimus (RAD001)
40	Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus	Completed	NCT00597506	Phase 2	Bevacizumab;Everolimus
41	Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma	Completed	NCT00165217	Phase 2	Capecitabine;Thalidomide
42	Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer	Recruiting	NCT03642067	Phase 2	Nivolumab;Relatlimab
43	Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas	Completed	NCT01730586	Phase 2	Abraxane
44	Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib	Completed	NCT00582660	Phase 2	Celecoxib;Placebo
45	Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver	Recruiting	NCT03069950	Phase 2	Floxuridine (FUDR);Irinotecan (CPT-11);FLUOROURACIL;PANITUMUMAB;DEXAMETHASONE;Leucovorin
46	Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer (Liver Resection With Unresectable Lung Nodules From Colorectal Adenocarcinoma - LUNA)	Recruiting	NCT02738606	Phase 2	Chemotherapy
47	Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF	Terminated	NCT01367275	Phase 2	Brivanib;Irinotecan
48	PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC	Recruiting	NCT03442569	Phase 2	Panitumumab;Nivolumab;Ipilimumab
49	Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer	Completed	NCT00003220	Phase 2	bryostatin 1
50	Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer	Completed	NCT00025350	Phase 2	gefitinib

Search NIH Clinical Center for Large Intestine Adenocarcinoma

Sources

Genetic Tests for Large Intestine Adenocarcinoma

Sources

Anatomical Context for Large Intestine Adenocarcinoma

MalaCards organs/tissues related to Large Intestine Adenocarcinoma:

⁴²

Liver, Colon, Lung, Kidney, Bone, Endothelial, T Cells

Sources

Publications for Large Intestine Adenocarcinoma

Sources

Genes for Large Intestine Adenocarcinoma

Genes related to Large Intestine Adenocarcinoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CTNNB1	Catenin Beta 1	Protein Coding	20.57	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
2	TP53	Tumor Protein P53	Protein Coding	18.44	GeneCards inferred via : Variants (show sections)
3	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	18.27	GeneCards inferred via : Variants (show sections)
4	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	18.02	GeneCards inferred via : Variants (show sections)
5	CREBBP	CREB Binding Protein	Protein Coding	17.82	GeneCards inferred via : Variants (show sections)

Sources

Variations for Large Intestine Adenocarcinoma

Sources

Expression for Large Intestine Adenocarcinoma

Search GEO for disease gene expression data for Large Intestine Adenocarcinoma.

Sources

Pathways for Large Intestine Adenocarcinoma

Pathways related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 68)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁷ Show member pathways Immune System ⁶⁷ Neutrophil degranulation ⁶⁷	13.72	CREBBP CTNNB1 ERBB2 PIK3CA TP53
2	TGF-Beta Pathway ⁶⁵ Show member pathways JAK-STAT Pathway ⁶⁵ JNK Pathway ⁶⁵ MAPK Family Pathway ⁶⁵ Regulation of eIF4 and p70S6K ⁶⁵ SOCS Pathway ⁶⁵	13.28	CREBBP ERBB2 PIK3CA TP53
3	Developmental Biology ⁶⁷ Show member pathways Axon guidance ⁶⁷	13.24	CREBBP CTNNB1 ERBB2 PIK3CA
4	Human cytomegalovirus infection ³⁸ Show member pathways Human immunodeficiency virus 1 infection ³⁸ Kaposi sarcoma-associated herpesvirus infection ³⁸	12.72	CREBBP CTNNB1 PIK3CA TP53
5	TNFR1 Pathway ⁶⁵ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²³ Apoptosis through Death Receptors ⁶⁵ Apoptotic Pathways Triggered By HIV1 ⁶⁵ DR3 Signaling ⁶⁵ Fas Signaling ⁶⁵ GITR Pathway ⁶⁵ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶⁷ TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶⁵ TRAIL Pathway ⁶⁵ TWEAK Pathway ⁶⁵	12.71	CREBBP CTNNB1 PIK3CA TP53
6	Focal Adhesion ¹ ³⁸ Show member pathways HGF Pathway ⁶⁵ Integrin-mediated Cell Adhesion ¹	12.68	CTNNB1 ERBB2 PIK3CA
7	NFAT and Cardiac Hypertrophy ⁶⁵ Show member pathways IGF1R Signaling ⁶⁵ Signaling Involved in Cardiac Hypertrophy ⁶⁵	12.65	CREBBP ERBB2 PIK3CA
8	PI3K-Akt signaling pathway ³⁸ Show member pathways Human papillomavirus infection ³⁸	12.6	CREBBP CTNNB1 ERBB2 PIK3CA TP53
9	Downstream signaling events of B Cell Receptor (BCR) ⁶⁷ Show member pathways Activation of RAS in B cells ⁶⁷ Signaling by the B Cell Receptor (BCR) ⁶⁷	12.53	ERBB2 PIK3CA TP53
10	Gastric cancer ³⁸ Show member pathways Breast cancer ³⁸ Hepatocellular carcinoma ³⁸	12.53	CTNNB1 ERBB2 PIK3CA TP53
11	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.49	ERBB2 PIK3CA TP53
12	Development HGF signaling pathway ²³ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²³ Apoptosis and survival NGF signaling pathway ²³ Apoptosis and survival Role of CDK5 in neuronal death and survival ²³ Development Neurotrophin family signaling ²³ MET activates PTPN11 ⁶⁷ MET activates STAT3 ⁶⁷ Neurotrophin signaling pathway ³⁸ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.49	CTNNB1 ERBB2 PIK3CA TP53
13	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.46	CREBBP CTNNB1 ERBB2 PIK3CA TP53
14	Influenza A ³⁸ Show member pathways Measles ³⁸	12.38	CREBBP PIK3CA TP53
15	Pathways in cancer ³⁸	12.38	CREBBP CTNNB1 ERBB2 PIK3CA TP53
16	Immune response IL-23 signaling pathway ²³ Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁵ Development Angiopoietin - Tie2 signaling ²³ Development PDGF signaling via STATs and NF-kB ²³ IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²³ Rac1/Pak1/p38/MMP-2 pathway ¹	12.34	CTNNB1 ERBB2 PIK3CA TP53
17	ErbB signaling pathway ¹ ³⁸ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶² EGFR tyrosine kinase inhibitor resistance ³⁸ Renal cell carcinoma ³⁸ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.33	CREBBP ERBB2 PIK3CA TP53
18	mTOR signaling pathway (KEGG) ⁶⁶ Show member pathways mTOR signaling pathway ³⁸	12.31	ERBB2 PIK3CA TP53
19	Prolactin Signaling Pathway ¹ ³⁸ Show member pathways Development Prolactin receptor signaling ²³ Leptin signaling pathway ¹	12.29	CREBBP ERBB2 PIK3CA
20	MicroRNAs in cancer ³⁸	12.27	CREBBP ERBB2 PIK3CA TP53
21	WNT Signaling ⁶⁵	12.23	CREBBP CTNNB1 TP53
22	G-protein signaling RAC1 in cellular process ²³ Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²³ RAC1 signaling pathway ¹	12.19	CTNNB1 ERBB2 PIK3CA
23	Apoptosis Pathway ⁷³ Show member pathways Akt Pathway ⁷³ NF-kappaB Pathway ⁷³	12.18	CTNNB1 ERBB2 PIK3CA TP53
24	Development Ligand-independent activation of ESR1 and ESR2 ²³ Show member pathways Transcription CREB pathway ²³ Transcription PPAR Pathway ²³	12.14	CREBBP ERBB2 PIK3CA
25	Wnt Signaling Pathway and Pluripotency ¹ Show member pathways Wnt Signaling Pathway ¹	12.11	CREBBP CTNNB1 TP53
26	Viral carcinogenesis ³⁸	12.11	CREBBP PIK3CA TP53
27	Human T-cell leukemia virus 1 infection ³⁸	12.07	CREBBP CTNNB1 PIK3CA TP53
28	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁶ Show member pathways Akt Signaling Pathway ⁶⁶	12.01	ERBB2 PIK3CA TP53
29	Proteoglycans in cancer ³⁸	12.01	CTNNB1 ERBB2 PIK3CA TP53
30	AKT Signaling Pathway ⁶⁸	11.95	ERBB2 PIK3CA TP53
31	Transcription Androgen Receptor nuclear signaling ²³ Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²³	11.94	CTNNB1 ERBB2 PIK3CA
32	Fluid shear stress and atherosclerosis ³⁸	11.91	CTNNB1 PIK3CA TP53
33	SMAD Signaling Network ⁶⁵	11.87	CREBBP CTNNB1 TP53
34	MAPK Pathway ⁷³ Show member pathways Toll-like Receptor Pathway ⁷³	11.85	ERBB2 PIK3CA TP53
35	Cell cycle Cell cycle (generic schema) ²³ Show member pathways Cell cycle Regulation of G1/S transition (part 2) ²³ G0 and Early G1 ⁶⁷ G2 Phase ⁶⁷	11.8	CREBBP CTNNB1 TP53
36	HIF-1 signaling pathway ³⁸	11.75	CREBBP ERBB2 PIK3CA
37	Glucocorticoid receptor regulatory network ¹	11.65	CREBBP TP53
38	Validated targets of C-MYC transcriptional activation ¹	11.64	CREBBP TP53
39	Bacterial invasion of epithelial cells ³⁸	11.6	CTNNB1 PIK3CA
40	Bladder cancer ³⁸ ¹	11.59	ERBB2 TP53
41	Platinum drug resistance ³⁸	11.59	ERBB2 PIK3CA TP53
42	Development_TGF-beta receptor signaling ²³	11.58	CREBBP ERBB2
43	Adherens junction ³⁸	11.57	CREBBP CTNNB1 ERBB2
44	Association Between Physico-Chemical Features and Toxicity Associated Pathways ¹	11.56	CTNNB1 ERBB2
45	p75(NTR)-mediated signaling ¹ Show member pathways Ceramide signalling ⁶⁷ NFG and proNGF binds to p75NTR ⁶⁷	11.54	PIK3CA TP53
46	Thyroid hormone signaling pathway ³⁸	11.52	CREBBP CTNNB1 PIK3CA TP53
47	Transcription_P53 signaling pathway ²³	11.51	CREBBP CTNNB1 TP53
48	Central carbon metabolism in cancer ³⁸	11.51	ERBB2 PIK3CA TP53
49	p53 pathway ¹	11.48	CREBBP TP53
50	TGF-beta Receptor Signaling (WikiPathways) ¹	11.48	CREBBP CTNNB1

Sources

GO Terms for Large Intestine Adenocarcinoma

Biological processes related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	viral process	GO:0016032	9.69	CREBBP CTNNB1 TP53
2	positive regulation of gene expression	GO:0010628	9.65	CTNNB1 ERBB2 TP53
3	cell proliferation	GO:0008283	9.61	CTNNB1 ERBB2 TP53
4	negative regulation of apoptotic process	GO:0043066	9.54	CTNNB1 TP53
5	cellular response to growth factor stimulus	GO:0071363	9.52	CTNNB1 ERBB2
6	embryonic digit morphogenesis	GO:0042733	9.49	CREBBP CTNNB1
7	cellular response to UV	GO:0034644	9.46	CREBBP TP53
8	regulation of angiogenesis	GO:0045765	9.4	CTNNB1 ERBB2
9	positive regulation of type I interferon production	GO:0032481	9.37	CREBBP CTNNB1
10	phosphatidylinositol 3-kinase signaling	GO:0014065	9.32	ERBB2 PIK3CA
11	ERBB2 signaling pathway	GO:0038128	9.26	ERBB2 PIK3CA
12	beta-catenin-TCF complex assembly	GO:1904837	9.16	CREBBP CTNNB1
13	regulation of apoptotic process	GO:0042981	9.13	CREBBP CTNNB1 TP53
14	vasculature development	GO:0001944	8.62	CTNNB1 PIK3CA

Molecular functions related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein heterodimerization activity	GO:0046982	9.63	CTNNB1 ERBB2 TP53
2	chromatin binding	GO:0003682	9.54	CREBBP CTNNB1 TP53
3	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	9.43	ERBB2 PIK3CA
4	transcription factor binding	GO:0008134	9.43	CREBBP CTNNB1 TP53
5	p53 binding	GO:0002039	9.4	CREBBP TP53
6	RNA polymerase II activating transcription factor binding	GO:0001102	9.32	CREBBP CTNNB1
7	disordered domain specific binding	GO:0097718	9.16	CTNNB1 TP53
8	protein phosphatase binding	GO:0019903	9.13	CTNNB1 ERBB2 TP53
9	RNA polymerase II transcription factor binding	GO:0001085	8.8	CREBBP CTNNB1 TP53

Sources

Sources for Large Intestine Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia